Immunocore Holdings plc

IMCR

US45258D1054

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
58.46 ^USD	+0.79%		+4.99%	-14.43%

Mar. 21	Immunocore Holdings Files Mixed-Securities Shelf Registration	MT
Mar. 14	Transcript : Immunocore Holdings plc Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:30 AM

Immunocore Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023

February 28, 2024 at 07:34 am EST

Immunocore Holdings plc reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 249.43 million compared to USD 174.36 million a year ago. Net loss was USD 55.29 million compared to USD 52.54 million a year ago.

Basic loss per share from continuing operations was USD 1.13 compared to USD 1.15 a year ago.

Latest news about Immunocore Holdings plc

Immunocore Holdings Files Mixed-Securities Shelf Registration	Mar. 21	MT
Transcript : Immunocore Holdings plc Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:30 AM	Mar. 14
Mizuho Securities Raises Immunocore Price Target to $90 From $86, Maintains Buy Rating	Mar. 04	MT
Oppenheimer Adjusts Immunocore Price Target to $87 From $85, Maintains Outperform Rating	Feb. 29	MT
Immunocore Holdings' Q4 Net Loss Narrows, Revenue Rises	Feb. 28	MT
Transcript : Immunocore Holdings plc, Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (IMCR) IMMUNOCORE HOLDINGS LIMITED Reports Q4 Revenue $70.2M, vs. Street Est of $68.5M	Feb. 28	MT
Immunocore Holdings plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Immunocore Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Immunocore Collaborates With Bristol Myers Squibb in Advanced Cutaneous Melanoma Trial	Feb. 22	MT
Mizuho Raises Price Target on Immunocore to $86 From $72 Ahead of Q4 2023 Earnings Announcement, Reiterates Buy Rating	Feb. 15	MT
Immunocore Prices Upsized $350 Million Convertible Notes Offering	Jan. 31	MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	Jan. 30	MT
Immunocore Plans $300 Million Convertible Senior Notes Offering ; Shares Fall After-Hours	Jan. 29	MT
Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023	Jan. 29	CI
Transcript : Immunocore Holdings plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:00 AM	Jan. 10
Immunocore Holdings Insider Sold Shares Worth $305,781, According to a Recent SEC Filing	Jan. 05	MT
Immunocore Plans to Boost Sales, Expand Access to Kimmtrak in 2024	Jan. 05	MT
Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline	Jan. 05	CI
Mizuho Cuts Price Target on Immunocore to $72 From $74, Reiterates Buy Rating	Nov. 10	MT
Immunocore Holdings plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Cantor Fitzgerald Initiates Coverage on Immunocore with Overweight Rating	Nov. 02	MT
Baird Initiates Immunocore With Outperform Rating, Price Target is $84	23-10-31	MT
Immunocore Says Metastatic Uveal Melanoma Therapy Showed Long-Term Survival Benefit in Late-Stage Trial	23-10-23	MT
Oppenheimer Adjusts Immunocore Price Target to $85 From $75, Maintains Outperform Rating	23-09-21	MT

Chart Immunocore Holdings plc

Duration

Period

More charts

Company Profile

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Immunocore Holdings plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

46.93 GBP

Average target price

67.36 GBP

Spread / Average Target

+43.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IMMUNOCORE HOLDINGS PLC	-14.43%	2.95B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals